Floatz logo

FLUOROURACILUM

Leukemia, B-Cell, Chronic

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Leukemia, B-Cell, Chronic cohort.

Asset / SponsorPhaseRating
Acadesine
Advancell - Advanced In Vitro Cell Technologies, S.A.
Phase 1/2CCC
Veltuzumab
Gilead Sciences
Phase 1/2CCC
Milatuzumab
Gilead Sciences
Phase 1/2CCC
Calcium folinate pentahydrate
OHSU Knight Cancer Institute
Phase 1CC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →